United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $541.39, for a total value of $5,143,205.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,933,333.07. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Price Performance
UTHR opened at $549.57 on Tuesday. The stock's 50 day simple moving average is $566.45 and its 200 day simple moving average is $522.10. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm has a market cap of $23.33 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 1.78 and a beta of 0.57.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the business earned $6.63 earnings per share. United Therapeutics's revenue was down 1.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current year.
Wall Street Analyst Weigh In
UTHR has been the topic of a number of recent analyst reports. Raymond James Financial initiated coverage on United Therapeutics in a research report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price objective on the stock. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. HC Wainwright lifted their price objective on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Finally, Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $619.42.
Get Our Latest Stock Analysis on United Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC purchased a new position in United Therapeutics during the 4th quarter valued at $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $31,000. International Assets Investment Management LLC lifted its stake in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 49 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
